Logo

SeeTreat at ESTRO 2024

We are thrilled to announce that SeeTreat will be well represented at ESTRO 2024 in Glasgow. Our CEO, Dr. Trang Nguyen, CPO, Dr. Sean Pollock, Director of Clinical Research, Prof. Paul Keall, and Dr Jeremy Booth will be in attendance from the 3rd to the 7th of May.

This year's theme of Radiation Oncology: Bridging the Care Gap, resounds strongly with SeeTreat's core value of providing equitable treatment to patients around the world.

This event offers a fantastic opportunity for us to showcase the exciting progress SeeTreat has made and explore potential partnerships. If you are attending ESTRO and would like to connect, please reach out to us, and we will facilitate a meeting with our team.

Related news

  • C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic
    Dr Trang Nguyen
    Dr Trang Nguyen29 September 2026

    C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic

    C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic UPPSALA, Sweden/SYDNEY, Australia – September 29, 2026 – C-RAD (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.

    Read more
  • ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy
    Dr Sean Pollock
    Dr Sean Pollock17 September 2026

    ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy

    SeeTreat co-founder Professor Paul Keall speaks with Sally Sara on innovating with radiotherapy. Prof Keall writes of this interview: "It was an honour to be invited to contribute to the ABC's Changing Australia series hosted by Sally Sara. On the question of how to bring innovations in radiotherapy to large numbers of patients I am proud that we at SeeTreat are doing just that: developing accessible technology to ensure that the radiation treatment is personalised to the patient throughout their course of therapy."

    Read more
  • SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA
    Antonia Dalton
    Antonia Dalton19 May 2026

    SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA

    SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.

    Read more